Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIAM phase 2 induction carboplatin + paclitaxel + pembrolizumab in locoregionally advanced penile cancer
NL-OMON60163Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, carboplatin and paclitaxel in penile squamous cell carcinoma (PSCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Pathological complete response in intention-to-treat population. Started Aug 2024; status: recruiting.
02
Drugs
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NL-OMON60163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60163.